TREAT CTC

BIG 1-12

Share This Post

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)

Toggle Content

This study is coordinated and sponsored by the EORTC, in collaboration with BCG, SUCCESS, UNICANCER and under the umbrella of the Breast International Group.

Pharmaceutical partners: Roche, Janssen Diagnostics

This study is funded by an educational grant from Roche and run under BIG’s Principles of Research Conduct.

More To Explore

RIBOLARIS

RIBOLARIS BIG 21-02 Share This Post Neoadjuvant and adjuvant RIBOciclib + endocrine therapy for cLinicAlly high-RISk ER+/HER2-negative breast cancer What This is a study being

Read More

OPTIMA

OPTIMA BIG 22-02 Share This Post Optimal personalised treatment of early breast cancer using multi-parameter analysis What Optimal personalised treatment of early breast cancer using

Read More